FDA decision: Vamikibart by Genentech (on or before July 31, 2027)

Kalshi Health › FDA & drugs Closes Jul 31, 2027 · $4 traded · prices read 11 h ago

Embed

The odds

63%chance▲ 1

How the odds have moved

Yes: 62% on Nov 2, 63% now.

Each outcome's chance over time on Kalshi. The dots along the bottom are headlines about its subject: point at one to read it.

Every outcome

Outcome Chance Day Bid Ask Pays Contracts
Yes 63% ▲ 1 59¢ 66¢ $1.52 6.00

"Pays" is what a $1 stake returns if that outcome happens, at the price shown (before any fees). Bid and ask are the best prices to sell and buy "Yes".

The news: FDA, Vamikibart, Genentech

Search ›
  • FDA grants tentative approval to low-cost HIV shotsemafor.com · 5 days agoThe potential rollout of a more affordable injection to help prevent HIV infection lifts hopes for reduced AIDS deaths in Africa. US regulators’ approval of a cheaper HIV shot has lifted hopes in some of the world’s poorest countries…
  • Pharma critic Bernie Sanders is set to hold major sway over FDA funding billSTAT · 5 days agoSTAT WASHINGTON – Democrats’ landslide victory in the midterm elections may have significant implications for the upcoming negotiations over a key funding source for the Food and Drug Administration in part by empowering a major critic of…
  • Regulatory and patent teams must align, say Amgen, Genentech, ORICLife Sciences IP Review · 5 days agoLife Sciences IP Review
  • FDA Recall Update: FebruaryPowder Bulk Solids · 4 days agoThere were 14 recalls in the food & beverage, pet food, and drugs sectors, a 25% decrease compared with last month. The US Food & Drug Administration (FDA) recalled 14 food and beverage, pet food, and drugs products, and updated a previous…
  • FDA Upgrades Recall of Gelatelli-Brand GelatoNTD · 3 days agoThe lot of Gelatelli coffee and vanilla gelato that was withdrawn from the market last month was flagged by the U.S. Food and Drug Administration (FDA) as a Class I recall event this week. Concerns about the potential for Listeria…
  • FDA Approves Amivantamab for Recurrent or Metastatic HNSCC@OncNursingNews · 3 days agoFDA grants accelerated approval to amivantamab and hyaluronidase-lpuj for recurrent or metastatic head and neck squamous cell carcinoma. The approval was based on cohort 1 of the open-label, multicenter phase 1b/2 OrigAMI-4 trial, which…
  • FDA probes tumour risk tied to Novartis gene therapyTradingView · 3 days agoTradingView FDA probes tumour risk tied to Novartis gene therapy
  • FDA Upgrades Frozen Blueberry RecallPowder Bulk Solids · 4 days agoThe federal agency classified the recalled product, sold by supermarket chain Publix, as Class I, which represents the highest level of risk. On Tuesday, the US Food & Drug Administration (FDA) upgraded a growing recall on frozen…
  • FlowStop Hemostatic Spray Hits 18,000 Units, Seeks FDA ClearanceBioSpace · 3 days agoSouth Korean maker INNOPHARMA designs the no-compression liquid spray for bystanders, firefighters and soldiers who reach injuries before medical care DAEGU, South Korea, Nov. 6, 2026 /PRNewswire/ -- A liquid spray lets people without…
  • FDA warns of risks with unapproved, compounded weight loss drugsAtlanta News First · 3 days agoWhat’s in this report: ATLANTA, Ga. (Atlanta News First) - The Food & Drug Administration (FDA) is warning patients and doctors about the risks of unapproved, compounded versions of popular GLP-1 weight loss drugs, the compounded copies of…
  • Generic drugs, implants & injectables being studied: Maharashtra FDA CommissionerBusinessLine · 3 days agoIn less than six months of Tukaram Mundhe taking charge as Maharashtra Food and Drug Administration’s Commissioner, the regulatory authority has undertaken over 33,000 inspections, close to 8,000 of them involving medicines. But there’s…
  • FDA Recall Update: October 2026Powder Bulk Solids · 4 days agoUndeclared ingredients was the reason for many recalls during the month. There were 26 recalls in the food & beverage sector, a notable increase over September. The US Food & Drug Administration (FDA) recalled 26 food & beverage products…

Related markets

All fda & drugs ›

Odds are traders' prices on Kalshi, Polymarket, ForecastEx and Crypto.com, not forecasts by 4Progressives. Prices read from the venues 5 min ago. Prices may be delayed. Money traded on Kalshi and ForecastEx is estimated from contracts. Not betting or investment advice.

Prediction-market prices are what traders pay for each outcome on Kalshi, Polymarket, ForecastEx and Crypto.com, read as the market's implied chance. They are not forecasts by 4Progressives, can move fast and can be wrong; they are read every few minutes and may be delayed. Money traded on Kalshi and ForecastEx is estimated from contracts at their price. News comes from the 4Progressives index; prices of stocks, rates and coins from 4Progressives Finance. Nothing here is betting, financial or investment advice. Terms of use. How to use Predictions